Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $624.53 million. The enterprise value is $276.83 million.
| Market Cap | 624.53M |
| Enterprise Value | 276.83M |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 70.57 million shares outstanding. The number of shares has increased by 5.54% in one year.
| Shares Outstanding | 70.57M |
| Shares Change (YoY) | +5.54% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 4.49% |
| Owned by Institutions (%) | 96.07% |
| Float | 41.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.22 |
| Forward PS | 5.73 |
| PB Ratio | 1.34 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.41 |
| Quick Ratio | 7.06 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.20% and return on invested capital (ROIC) is -28.09%.
| Return on Equity (ROE) | -26.20% |
| Return on Assets (ROA) | -20.30% |
| Return on Capital (ROIC) | -28.09% |
| Revenue Per Employee | $279,456 |
| Profits Per Employee | -$436,301 |
| Employee Count | 272 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -568,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.52% in the last 52 weeks. The beta is 1.11, so Zymeworks's price volatility has been higher than the market average.
| Beta (1Y) | 1.11 |
| 52-Week Price Change | -10.52% |
| 50-Day Moving Average | 10.76 |
| 200-Day Moving Average | 8.83 |
| Relative Strength Index (RSI) | 32.41 |
| Average Volume (30 Days) | 574,269 |
Short Selling Information
The latest short interest is 5.03 million, so 7.13% of the outstanding shares have been sold short.
| Short Interest | 5.03M |
| Short Previous Month | 3.96M |
| Short % of Shares Out | 7.13% |
| Short % of Float | 12.10% |
| Short Ratio (days to cover) | 7.69 |
Income Statement
In the last 12 months, Zymeworks had revenue of $76.01 million and -$118.67 million in losses. Loss per share was -$1.72.
| Revenue | 76.01M |
| Gross Profit | 76.01M |
| Operating Income | -138.05M |
| Pretax Income | -119.24M |
| Net Income | -118.67M |
| EBITDA | -101.94M |
| EBIT | -119.24M |
| Loss Per Share | -$1.72 |
Balance Sheet
The company has $374.33 million in cash and $26.63 million in debt, giving a net cash position of $347.70 million or $4.93 per share.
| Cash & Cash Equivalents | 374.33M |
| Total Debt | 26.63M |
| Net Cash | 347.70M |
| Net Cash Per Share | $4.93 |
| Equity / Book Value | 464.81M |
| Book Value Per Share | 6.59 |
| Working Capital | 357.16M |
Cash Flow
In the last 12 months, operating cash flow was -$118.30 million and capital expenditures -$2.47 million, giving a free cash flow of -$120.78 million.
| Operating Cash Flow | -118.30M |
| Capital Expenditures | -2.47M |
| Free Cash Flow | -120.78M |
| FCF Per Share | -$1.75 |
Margins
Gross margin is 100.00%, with operating and profit margins of -181.62% and -156.13%.
| Gross Margin | 100.00% |
| Operating Margin | -181.62% |
| Pretax Margin | -156.87% |
| Profit Margin | -156.13% |
| EBITDA Margin | -134.11% |
| EBIT Margin | -156.87% |
| FCF Margin | -158.89% |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.54% |
| Shareholder Yield | -5.54% |
| Earnings Yield | -19.00% |
| FCF Yield | -19.34% |
Analyst Forecast
The average price target for Zymeworks is $15.25, which is 72.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.25 |
| Price Target Difference | 72.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 6.98% |
| EPS Growth Forecast (5Y) | -0.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 1.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.79 |
| Piotroski F-Score | 3 |